TB) 2 12 Abstract 13 N-terminal acetylation is one of the most common post-translational 14 modifications of the eukaryotic proteome and regulates numerous aspects of 15 cellular physiology, such as protein folding, localization and turnover. In 16 particular α-synuclein, whose dyshomeostasis has been tied to the pathogenesis 17 of several neurodegenerative disorders, is completely N α -acetylated in nervous 18 tissue. In this work, building on previous reports, we develop and characterize a 19 bacterial N-terminal acetylation system based on the expression of the yeast N-20 terminal acetyltransferase B (NatB) complex under the control of the P BAD (L-21 arabinose-inducible) promoter. We show its functionality and the ability to 22 completely N α -acetylate our model substrate α-synuclein both upon induction of 23 the construct with L-arabinose and also by only relying on the constitutive 24 expression of the NatB genes. 25 26 Introduction 27 Protein N α -acetylation, or N-terminal acetylation, is one of the most common 28 post-translational modifications (PTMs) of the eukaryotic proteome, with a vast 29 majority of all N-termini (~80%) bearing this moiety. The reaction is catalyzed 30 by a class of enzymes, N-terminal acetyltransferases (NATs), of which six (NatA 31 to NatF) have to-date been discovered in humans and one (NatG) has been 32 identified in Arabidopsis thaliana, with no human ortholog [1]. These enzymes 33 mediate the transfer of an acetyl group from acetyl-CoA to the positively charged 34 N-terminus of the protein. Their activity often requires the formation of a 35 complex with the ribosome, mediated by one or two auxiliary, ribosome-3
5 85 53613) [20] . Mutagenesis of the pNatB construct to correct the A2520G mutation 86 was performed using the QuikChange II site-directed mutagenesis kit (Agilent 87 Technologies, Santa Clara, CA) and primers G2520A FWD 5'-88 CGTCGTTTGAATGTATGAATCGATCATTCCTTCACCAAC-3' and G2520A REV 5'-89 GTTGGTGAAGGAATGATCGATTCATACATTCAAACGACG-3'; to insert a PvuI 90 restriction site in pTSara, upstream of the T7Te terminator, the primers PvuI 91 FWD 5'-TGTGATCCAAGCCAGCTCGATCGCCGTCGGCTTG-3' and PvuI REV 5'-92 CAAGCCGACGGCGATCGAGCTGGCTTGGATCACA-3' were used. The Naa20 insert 93 in pNatB_G2520A was PCR-amplified using the primers Naa20 FWD 5'-94 TTGGGCTAGCACTAGTTATAAGAAGGAGATATACATATG-3' and Naa20 REV 5'-95 ATGCCTGCAGGTCGACCTAAAATGAAACATCAGCTGG-3' and inserted into 96 pTSara_PvuI (linearized with SpeI/SalI) using the In-Fusion HD Cloning Kit 97 (Takara Bio, Mountain View, CA). The Naa25 insert in pNatB_G2520A was PCR-98 amplified using the primers Naa25 FWD 5'-99 TTTTTTGGGCTAGCGAGCTCTATAAGAAGGAGATATACATATGCGTCGTTCTGGGAG
100
TAAAGAATC-3' and Naa25 REV 5'-101 ATCCAAGCCAGCTCGATCGCTAAAATTTTACAAATTTTGGAAGCTTGCT-3' and 102 inserted into pTSara_PvuI-Naa20 (linearized with SacI/PvuI) using the In-Fusion 103 HD Cloning Kit (Takara Bio, Mountain View, CA). Cloning of pTSara_PvuI-Naa20- and starting from the bicistronic construct pTSara [24], we cloned both the 10 206 catalytic, Naa20, and regulatory, Naa25, subunit into pTSara, maintaining the 207 ribosome-binding region of pACYC-Duet-1 (a previously reported missense A-to-208 G mutation in the Naa25 gene [25] was also corrected), ( Fig 1A) and called the 209 construct pTSara-NatB. We then verified the success of the expression by CBB-210 stained SDS-PAGE and immunoblotting of Naa20 and Naa25 (Fig 1B and C) .
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